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Development of a syngeneic mouse model of
epithelial ovarian cancer
Bridget A Quinn1,5, Fang Xiao1, Laura Bickel1, Lainie Martin1, Xiang Hua2, Andres Klein-Szanto3,4,
Denise C Connolly1*

Abstract
Background: Most cases of ovarian cancer are epithelial in origin and diagnosed at advanced stage when the
cancer is widely disseminated in the peritoneal cavity. The objective of this study was to establish an
immunocompetent syngeneic mouse model of disseminated epithelial ovarian cancer (EOC) to facilitate laboratorybased studies of ovarian tumor biology and preclinical therapeutic strategies.
Methods: Individual lines of TgMISIIR-TAg transgenic mice were phenotypically characterized and backcrossed to
inbred C57BL/6 mice. In addition to a previously described line of EOC-prone mice, two lines (TgMISIIR-TAg-Low)
were isolated that express the oncogenic transgene, but have little or no susceptibility to tumor development.
Independent murine ovarian carcinoma (MOVCAR) cell lines were established from the ascites of tumor-bearing
C57BL/6 TgMISIIR-TAg transgenic mice, characterized and tested for engraftment in the following recipient mice:
1) severe immunocompromised immunodeficient (SCID), 2) wild type C57BL/6, 3) oophorectomized tumor-prone
C57BL/6 TgMISIIR-TAg transgenic and 4) non-tumor prone C57BL/6 TgMISIIR-TAg-Low transgenic. Lastly, MOVCAR
cells transduced with a luciferase reporter were implanted in TgMISIIR-TAg-Low mice and in vivo tumor growth
monitored by non-invasive optical imaging.
Results: Engraftment of MOVCAR cells by i.p. injection resulted in the development of disseminated peritoneal
carcinomatosis in SCID, but not wild type C57BL/6 mice. Oophorectomized tumor-prone TgMISIIR-TAg mice
developed peritoneal carcinomas with high frequency, rendering them unsuitable as allograft recipients. Orthotopic
or pseudo-orthotopic implantation of MOVCAR cells in TgMISIIR-TAg-Low mice resulted in the development of
disseminated peritoneal tumors, frequently accompanied by the production of malignant ascites. Tumors arising in
the engrafted mice bore histopathological resemblance to human high-grade serous EOC and exhibited a similar
pattern of peritoneal disease spread.
Conclusions: A syngeneic mouse model of human EOC was created by pseudo-orthotopic and orthotopic
implantation of MOVCAR cells in a susceptible inbred transgenic host. This immunocompetent syngeneic mouse
model presents a flexible system that can be used to study the consequences of altered gene expression (e.g., by
ectopic expression or RNA interference strategies) in an established MOVCAR tumor cell line within the ovarian
tumor microenvironment and for the development and analysis of preclinical therapeutic agents including EOC
vaccines and immunotherapeutic agents.

Background
Ovarian cancer is the most common cause of death
from gynecologic malignancies and the fifth most common cause of cancer death in women in the United
States [1]. Ovarian adenocarcinomas account for 85-90%
* Correspondence: Denise.Connolly@fccc.edu
1
Women’s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue,
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of all cancers of the ovary. The initiating cell population
for EOC remains to be exactly defined, with different
evidence suggesting tumors originate from the ovarian
surface epithelium (OSE), inclusion cysts lined by OSE
[2-5] or alternatively, the fallopian tube epithelium [6]
or components of the secondary Müllerian system,
including the epithelial cells of the rete ovarii, paraovarian/paratubal cysts, endosalpingiosis, endometriosis or
endomucinosis [7]. The lack of clarity regarding tumor
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origin stems from the fact that unlike epithelial cancers
arising in other organs, a well-defined disease spectrum
consisting of benign, invasive and metastatic lesions has
not been identified for EOC. This is due at least in part
to that fact that the majority of cases are identified at
advanced stage when disease has spread beyond the
ovary. Another reason is the morphologic complexity of
common EOCs which consist of several distinct histologic subtypes; these include serous, endometrioid, mucinous and clear cell cancers.
Progress in ovarian cancer research has been slowed
by the lack of suitable animal models that exhibit features of human disease. Genetically manipulable mammalian models of spontaneous ovarian cancer are rare,
particularly those representing ovarian adenocarcinomas.
Human and rodent models of spontaneous ex vivo
transformation of OSE have been described [8-10]. One
of these models, a syngeneic mouse model of EOC [10],
has been extensively used for preclinical studies of therapeutic agents and studies of the tumor microenvironment [11-18]. Early attempts to produce murine EOC
models using transgenic or other genetic engineering
approaches resulted in the development of granulosa
cell tumors [19-24]. More recently, a number of laboratories have developed genetically engineered mouse
(GEM) models of EOC by using ex vivo transformation
[25,26], transgenic [27,28] and conditional gene expression strategies [29-31]. To date, due to the lack of a suitable GEM model expressing Cre-recombinase, the
strategy most frequently employed for conditional gene
expression in the ovarian epithelium involves survival
surgery for intrabursal injection of recombinant Adenovirus-Cre [29-34].
Recently, our group developed a spontaneous transgenic mouse model of EOC by expressing the oncogenic
early region of SV40 under the transcriptional control of
the Müllerian inhibiting substance type II receptor gene
promoter [27,28]. Although SV40 TAg expression is not
directly associated with the development of human cancer, its expression results in functional inactivation of
the critical tumor suppressors p53 and Rb. Mutation of
TP53 is, by far, the most common genetic alteration
observed in EOC, particularly the serous subtype
[35,36]. Direct mutation or loss of Rb or its downstream
signaling mediators are also common in EOCs [37-41].
Via binding and inhibition of PP2A, SV40 tag also
results in activation of PI3K/AKT and mitogen activated
protein kinase (MAPK) signaling [42], pathways frequently activated in human EOC [43]. A stable transgenic line of TgMISIIR-TAg mice was established in
which female mice develop bilateral ovarian carcinoma
with 100% penetrance [28]. To date, this is the only
GEM model that develops spontaneous EOC with
pathological features of serous EOC that does not
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require extensive surgical manipulation to induce the
phenotype. Like human EOC, female TgMISIIR-TAg
mice with significant tumor burden exhibit no apparent
symptoms of illness and disease dissemination is typically restricted to the peritoneum [27,28]. Murine ovarian carcinoma (MOVCAR) cell lines isolated from the
ascites and primary tumors of these mice share many
molecular features with human tumors [27,28,44-48]
and are well suited to experimental analysis in vitro.
With these reagents, the expression levels of specific
genes can be experimentally manipulated and properties
of MOVCAR cell lines can be assessed in vitro. However, the lack of a syngeneic recipient for manipulated
MOVCAR cells has limited the analysis of the in vivo
effects of genetic alterations in the model to studies in
immunodeficient mice. The present study describes the
identification of non-tumor prone lines of TgMISIIRTAg transgenic mice that can be used as syngeneic recipients for MOVCAR cell allografts. The availability of
this syngeneic model affords the opportunity to study
the in vivo effects of genetic alterations on tumor properties and on interactions between tumor cells and their
microenvironment in an immunocompetent host. Moreover, this immunocompetent mouse model of EOC is
suitable for studies of immune-based therapeutic strategies and vaccine development.

Methods
Transgenic mice and backcrosses

All procedures involving mice were approved by the Fox
Chase Cancer Center (FCCC) Institutional Animal Care
and Use Committee (IACUC) and all mice were maintained under specific pathogen free conditions. Individual transgenic TgMISIIR-TAg founder mice were
generated in the FCCC Transgenic Facility in a first
generation hybrid genetic background of C57BL/6 and
C3H (B6C3F1) and genotyped by PCR amplification as
previously described [27]. Transgenic founders were
crossed with wild type C57BL/6 mice (obtained from
the FCCC Laboratory Animal Facility) to establish
breeding lines. Relevant lines of EOC-prone and nontumor-prone TgMISIIR-TAg mice were maintained as
hemizygotes and backcrossed for a minimum of ten
generations to wild type C57BL/6 mice to generate
genetically pure lines of C57BL/6 TgMISIIR-TAg mice.
Cell lines and culture conditions

Pure C57BL/6 MOVCAR cell lines, including MOVCAR
12, 5009 [49], 5025, 5183, 5438, 5447 and 5612, were
established from bulk ascites isolated from individual
ovarian tumor-bearing C57BL/6 TgMISIIR-TAg mice as
previously described [27]. Tumorigenic spontaneously
transformed murine ovarian surface epithelial cell
(MOSEC) lines ID-8, IF-5 and IG-10 were a gift from
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Dr. Katherine Roby, University of Kansas Medical Center, and ID-8 cells stably overexpressing murine
VEGF164 were a gift from Dr. George Coukos, University of Pennsylvania. All MOVCAR and MOSEC cells
were maintained in DMEM supplemented with 4% FBS,
1× Insulin/Transferrin/Selenium-A (ITS, supplied as
100× stock from Gibco/Invitrogen), penicillin/streptomycin (100 units/mL and 100 μg/mL, respectively) and
2 mM l-glutamine and incubated at 37°C in 5% CO 2 .
Culture medium was changed once weekly and cells
were trypsinized and passaged at 4-5 day intervals when
they reached confluence. MOVCAR cells were prepared
for in vivo injection as described [49]. For in vivo imaging, cells were transduced with a retroviral construct
encoding the firefly luciferase gene (pWZL-Luc, generously provided by Dr. Maureen Murphy, FCCC) using
standard methods.
Immunoblot and immunoprecipitation

To prepare lysates for immunoblot analysis, cells were
washed with cold PBS, lysed with M-PER mammalian
protein extraction reagent (Thermo Scientific, Rockford,
IL) supplemented with a cocktail of protease inhibitors
(Complete Mini, Roche, Indianapolis, IN) and protein
concentration was determined by BCA method (Thermo
Scientific, Rockford, IL). Equal amounts of protein samples were resolved by SDS-PAGE gel electrophoresis on
12% acrylamide gels and transferred to polyvinylidene
difluoride membrane (Immobilon, Millipore Corp., Bedford, MA). Membranes were blocked in 5% milk and
0.1% Tween-20 in 1× PBS for 1 h prior to incubation
with primary antibodies recognizing SV40 TAg (Pab
101) and mouse p53 (Pab 240) obtained from Santa
Cruz Biotechnology, Inc. at 1:1000 dilution. Horseradish
peroxidase-conjugated secondary antibodies were used
according to manufacturer’s protocols. Immunoreactivity
was visualized using the ECL system and was exposed to
BioMax MR film (Eastman Kodak Co.).
For immunoprecipitation, cells were grown in 100-mm
plates and lysed in 1 ml M-PER mammalian protein
extraction reagent. The whole cell lysates were incubated with SV40 TAg antibody (Pab101) at a dilution of
1:100 at 4°C overnight with constant mixing. Protein A
beads (40 μl) were added and mixed for 3 h at 4°C.
Immunoprecipitates were then washed 5 times with MPER mammalian protein extraction reagent and pellets
resuspended in Laemli buffer for protein electrophoresis
and immunoblot blot analysis performed as described
above with antibodies against TAg and p53.
Cell cycle analysis

Cells were prepared for cell cycle analysis using the
fluorescent nuclear stain propidium iodide and fluorescent sorting was carried out using the Guava Personal
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Cell Analysis machine exactly as described by the manufacturer (Guava Technologies).
RNA preparation, quantitative reverse transcription PCR

Total RNA was isolated from MOVCAR cells using the
RNA Easy Mini Kit (Qiagen). With the assistance of the
FCCC Genomics Facility, levels of Mdm2 mRNA
expression were evaluated by real-time quantitative
reverse transcription PCR (qRT-PCR) using Taqman
technology with probe sets for Mdm2 and Hprt1
obtained from Applied Biosystems, Carlsbad, CA.
Quantitation of secreted VEGF by ELISA

Cells (5 × 105) were plated in triplicate in 6-well dishes
and grown in complete medium for 72 hours. The conditioned culture medium was removed and the level of
secreted VEGF present in the medium was determined
by ELISA using the Mouse VEGF Quantikine Elisa Kit
(R&D systems, Minneapolis, MN). After removal of the
conditioned culture supernatant, cells were immediately
rinsed with PBS, trypsinized and the number of cells
present in each well was counted. Secreted VEGF levels
were normalized to the total number of cells present in
the sample to determine the amount of VEGF/104 cells.
Three independent assays were performed and the
amount of secreted VEGF/10 4 cells expressed as the
mean value for each cell line tested.
Oophorectomy and MOVCAR cell allografts

Four to six week-old ovarian tumor-prone TgMISIIRTAg mice were anesthetized by i.p. injection of 95 μl per
10 gram body weight of 10 mg/mL Ketamine hydrochloride and 1 mg/mL Xylazine hydrochloride in sterile
saline and subjected to oophorectomy using a standard
asceptic surgical procedure commonly used for transgenic embryo injection to expose the ovarian fat pad
and ovary (described in detail in [49]). Once exposed, a
small incision was made in the ovarian bursa that
enabled removal of the resident ovary and/or fallopian
tube. The ovarian bursa was sealed with surgical glue
and the reproductive tract returned through the incision
in the body wall. The surgical incision was closed with
wound clips. The same surgical procedure was used for
orthotopic (i.b.) injection of MOVCAR cells into recipient mice. Methods for i.b. and i.p. (pseudo-orthotopic)
injections of MOVCAR cells were previously described
in detail [49].
Preparation and analysis of tissues, histology and
immunohistochemistry

All mice were euthanized by CO2 asphyxiation, necropsied and examined for gross abnormalities. Pathologically altered organs, entire reproductive tracts and
representative specimens of multiple organs and tissues,
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including the brain, lung, liver, kidney, spleen, pancreas
and intestine were removed at necropsy, fixed in 10%
(v/v) neutral buffered formalin (NBF) overnight, transferred to 70% ethanol and paraffin-embedded. In mice
with evident tumor, specimens of the tumor tissue were
also excised, snap frozen in liquid N2 and stored at -80°
C. For histological analysis, 5 μm formalin fixed paraffin
embedded tissue sections were cut for either H&E staining or immunohistochemistry (IHC). Histopathological
analysis was performed by a pathologist with expertise
in human and murine malignancies (AKS).
Sections of tumor tissue for IHC staining were cut on
SuperFrost Plus charged slides (Fisher). Unstained sections were deparaffinized, subjected to antigen retrieval
and stained with antibody against SV40 TAg (Pab 101,
1:100) as described [27].
Bioluminescent imaging (BLI)

For detection of in vivo growth of pWZL-Luc transduced MOVCAR tumor cells, mice were anesthetized
with 2% isofluorane and given i.p. injections of 100 mg/
kg luciferin substrate (Caliper Life Sciences) ten minutes
prior to imaging using the IVIS Spectrum in vivo imaging system (Caliper Life Sciences) as described [49].
Image analysis was performed and total flux emission
(photons/second) in the region of interest (ROI) was
determined using the Living Image Software for the
IVIS Spectrum.

Results
Allografted MOVCAR cells grow in immunodeficient mice,
but not in wild type C57BL/6 mice

Previous work showed that MOVCAR cell lines could
be readily established from the malignant ascites of individual female TgMISIIR-TAg founder mice with ovarian
tumors and that these cells were tumorigenic in immunocompromised SCID mice [27]. Subsequently, MOVCAR cell lines have been isolated from the EOC-bearing
female offspring of a fully penetrant stable transgenic
line of EOC-prone mice, TgMISIIR-TAg-DR26, derived
from a male founder [28]. These cells exhibited the
capacity for pseudo-orthotopic tumor growth giving rise
to disseminated peritoneal tumors in SCID mice similar
to advanced EOC observed in humans (data not shown).
While the ability to grow tumor cells in vivo in immunodeficient animals is highly valuable for tumor biology
studies, it is somewhat limited in that important contributions of immune cell signaling in the tumor microenvironment are lacking. Therefore, the ability to grow
tumor cells in a syngeneic host is highly desirable. In
establishing such a model, important considerations
include the genetic background of both the host from
which the tumor cells were isolated and the recipient
animal into which they will be allografted. An additional
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consideration is the potential immunogenicity of
the transgene protein product if it is not expressed
endogenously in wild type mice, as is the case for SV40
TAg. All TgMISIIR-TAg transgenic mice were initially
established in a B6C3F1 first generation hybrid genetic
background and maintained by crossing to wild type
C57BL/6 mice, thus resulting in a mixed genetic background of the offspring and any cell lines derived from
these mice. To address this issue, male TgMISIIR-TAgDR6 mice were maintained as hemizygotes with respect
to the TAg transgene and backcrossed to wild type
female C57BL/6 mice for a minimum of ten generations
to ensure >99% purity of the C57BL/6 genetic background. No changes in either tumor latency or TAg
expression patterns in ovarian tumors and reproductive
tracts of female mice were observed during the process
of backcrossing. Several new MOVCAR cell lines
(MOVCAR 12, 5009, 5025, 5438, 5447 and 5612) were
established from the ascites of ovarian tumor bearing
pure C57BL/6 TgMISIIR-TAg-DR6 mice and tested for
tumorigenic potential following i.p. injection of 5 × 106
- 1 × 107 cells in SCID mice. Tumors developed within
one to five months in SCID mice injected with all six
cell lines tested (Figure 1, Table 1 and data not shown).
In addition to the presence of peritoneal tumor nodules
on the pancreas, omentum, mesentery, body wall and
diaphragm, several of the SCID mice exhibited grossly
enlarged ovaries at necropsy and histopathological
review of H&E and TAg stained sections confirmed the
presence of TAg positive tumor around and within the
ovarian cortex. Tumors exhibited histology similar to
high-grade serous ovarian carcinomas in women. Next,
we similarly tested the tumorigenicity of MOVCAR cells
in wild type C57BL/6 mice (n= 5 - 10 mice/group).
Although each cell line tested was tumorigenic in SCID
mice, none of the cell lines engrafted in immunocompetent wild type C57BL/6 mice (Table 1 and data not
shown). The lack of tumor development in the immunocompetent C57BL/6 mice suggests, as previous studies
have shown [50], that the expression of TAg proteins in
the MOVCAR cells was immunogenic in wild type
C57BL/6 recipients.
Analysis of SV40 TAg expression and function in MOVCAR
cell lines

One of the principle mechanisms of oncogenicity of
SV40 virus is the capacity of the large TAg protein to
bind to and functionally inactivate the p53 and Rb
tumor suppressor proteins [51]. Expression of the large
TAg protein was verified by Western blot in all of the
MOVCAR cell lines, but absent in murine NIH3T3 cells
(data not shown) or MOSEC cell lines IF-5, ID-8, and
IG-10 (Figure 2A). In cells expressing wild type p53, p53
protein is kept at low, typically undetectable levels by
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Figure 1 Cell lines derived from C57BL/6 mice are tumorigenic in SCID mice. Individual MOVCAR cell lines isolated from C57BL/6 mice
(MOVCAR 12, 5612, 5447 and 5438) were tested for tumorigenicity in SCID mice by i.p. injection of 0.5 - 1.0 × 107 cells. H&E stained sections
show the presence of tumor cells in the ovary (a-d) and peritoneum (i-l). The tumors derived from all cell lines were poorly differentiated
carcinomas. The neoplastic cells were usually arranged in solid sheets and occasionally formed glandular structures and/or irregular slit-like
spaces. On the peritoneal surface, these cells also formed papillary structures. Immunohistochemical detection of TAg (e-h and m-p) shows
positively staining tumor cells with no staining of surrounding normal tissue. All micrographs were taken at the same magnification and the
calibration bar shown in panel p corresponds to 100 μm.

ubiquitin mediated proteasomal degradation [52]. However, in cells expressing SV40 Large TAg, p53 protein
remains bound to the TAg, resulting in p53 protein stabilization [52]. Consistent with these previous observations and our own published results showing p53
protein stabilization in TgMISIIR-TAg ovarian tumors
[27], we observed consistently high levels of p53 protein
in MOVCAR cell lines, but not in MOSEC cell lines IF5, ID-8, and IG-10 or NIH3T3 cells (Figure 2A and data
not shown). Physical interaction of the TAg and p53
proteins in MOVCAR cells was confirmed by coimmunoprecipitation assay. Whole cell lysates immunoprecipitated with a TAg-specific antibody (Pab 101) and
probed for p53 showed that p53 protein co-precipitated
with TAg in all of the MOVCAR cells tested (Figure 2A,

lower panels). To confirm that TAg binding results in
the functional abrogation of p53, MOVCAR cells were
treated with 200 nM etoposide for 0, 8 and 24 hours.
The capacity for a p53-mediated response to etoposide
treatment was assessed by evaluation of p53 protein
expression and stabilization, induction of the p53
responsive gene Mdm2 and induction of cell cycle
arrest. Treatment of the TAg negative ID-8 cells with
etoposide resulted in induction and stabilization of p53
protein (Figure 2B), suggesting that p53 is functional in
these cells. However, in TAg expressing MOVCAR cells,
p53 protein was already stabilized and no further induction or stabilization of p53 was observed in the etoposide treated compared to untreated cells (Figure 2B). In
etoposide treated ID-8 cells, qRT-PCR analysis showed

Quinn et al. Journal of Ovarian Research 2010, 3:24
http://www.ovarianresearch.com/content/3/1/24

Page 6 of 17

Table 1 Growth of MOVCAR cells in C57BL/6 and SCID mice
Host

MOVCAR cell line

# cells injected i.p.

Survival
(days post tumor cell injection)

Tumor location

C57BL/6

12

1 × 107

243

None

C57BL/6
C57BL/6

12
12

1 × 107
1 × 107

256
256

None
None

C57BL/6

12

1 × 107

256

None

C57BL/6

12

2 × 107

326

None

C57BL/6

12

2 × 107

326

None

C57BL/6

12

3 × 107

208

None

C57BL/6

12

3 × 107

208

None

C57BL/6

12

3 × 107

303

None

C57BL/6
SCID

12
12

3 × 107
1 × 107

303
93

None
Peritoneal cavity, invasion of ovarian cortex

+

SCID

12

1 × 107

100

Peritoneal cavity, invasion of ovarian cortex

+

SCID

12

1 × 107

103

Peritoneal cavity, invasion of ovarian cortex

+

SCID

12

1 × 107

103

Peritoneal cavity, invasion of ovarian cortex

+

SCID

12

1 × 107

105

Peritoneal cavity, invasion of ovarian cortex

+

SCID

5009

1 × 107

25

Peritoneal cavity

+

SCID

5009

1 × 107

25

Peritoneal cavity

+

SCID
SCID

5009
5009

1 × 107
1 × 107

34
34

Peritoneal cavity
Peritoneal cavity

+
+

SCID

5009

1 × 107

34

Peritoneal cavity

+

SCID

5009

1 × 107

34

Peritoneal cavity

+

SCID

5183

1 × 107

109

Peritoneal cavity, invasion of ovarian cortex

+

SCID

5183

1 × 107

116

Peritoneal cavity, invasion of ovarian cortex

SCID

5183

1 × 107

116

Peritoneal cavity, invasion of ovarian cortex

SCID

5348

1 × 107

141

Peritoneal cavity

+

SCID
SCID

5348
5348

1 × 107
5 × 106

141
141

Peritoneal cavity, invasion of ovarian cortex
Peritoneal cavity

+
+

SCID

5447

1 × 107

95

Peritoneal cavity, invasion of ovarian cortex

+

SCID

5447

1 × 107

95

Peritoneal cavity, invasion of ovarian cortex

+

SCID

5447

5 × 106

95

Peritoneal cavity

SCID

5447

5 × 106

97

Peritoneal cavity, invasion of ovarian cortex

SCID

5612

1 × 107

74

Peritoneal cavity, invasion of ovarian cortex

SCID

5612

5 × 106

97

Peritoneal cavity

greater than four-fold induction of Mdm2 expression
(Figure 2C) and cell cyle analysis showed growth arrest
indicated by accumulation of cells in G2/M (Figure 2D).
None of the similarly treated TAg positive MOVCAR
cell lines exhibited robust induction Mdm2 expression
or G2/M growth arrest. Taken together, these results
confirm the functional activity of TAg in MOVCAR cell
lines.
VEGF secretion in MOVCAR cell lines

In culture, MOVCAR cells exhibit differences in growth
rates and expression of signaling proteins associated
with EOC, including VEGF among others (Additional
file 1, Table S1 and data not shown). Differences in
tumor growth rates and ascites production among different MOVCAR cell lines were also apparent in vivo.

Ascites
(>1.0 mL)

+
+

Peritoneal implantation of MOVCAR 5009 or 5025 cells
in SCID mice resulted in rapid tumor growth and the
production of voluminous ascites that necessitated
euthanasia within 4-6 weeks. In SCID mice injected
with MOVCAR 5183, 5438, 5447 and 5612 cells, the
time to development of tumors necessitating euthanasia
was between 12 and 20 weeks and mice generally exhibited lower volumes of ascites at the time of necropsy
(Table 1 and data not shown). The cell lines expressing
the highest levels of secreted VEGF in vitro (e.g., MOVCAR 5009 and 5025) resulted in more rapid tumor
growth and ascites production in vivo than cell lines
with lower VEGF levels. This observation is consistent
with a previous study showing that enforced expression
of VEGF in the spontaneously transformed MOSEC line
ID-8 led to more aggressive in vivo tumor growth and
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Figure 2 Analysis of SV40 TAg expression and function in MOVCAR cells. A) Whole cell lysates of spontaneously transformed MOSEC lines
(IF-5, ID-8 and IG-10) and MOVCAR cell lines (12-3, 5025, 5183, 5438, 5447, 5612 and 5009) were evaluated by immunoblot analysis to determine
relative levels of SV40 TAg, p53 and Actin (loading control) protein expression. Lysates were also immunoprecipitated with anti-TAg antibody
Pab 101 followed by immunoblot analysis of TAg and p53 protein present in the immunoprecipitates. B) Induction of p53 protein was evaluated
by immunoblot following treatment of ID-8 and MOVCAR 5025, 5447 and 5612 cells with 200 nM etoposide for 0, 8 and 24 hr. C) Levels of
Mdm2 gene expression in ID-8 and MOVCAR 5025, 5447 and 5612 cells following treatment with 200 nM etoposide for 0, 8 and 24 hr were
evaluated by qRT-PCR. D) Cell cycle analysis was performed on ID-8 and MOVCAR 5025, 5447 and 5612 cells following treatment with 200 nM
etoposide.

more ascites production than the parental cell line [18].
Like individual MOSEC lines [10], the results also suggest that although MOVCAR cell lines are derived from
ascites from an inbred strain of transgenic mice, individual cell lines exhibit intrinsic differences.

Oophorectomized C57BL/6 TgMISIIR-TAg-DR6 mice
develop intrabursal and disseminated peritoneal
carcinomas

In order to identify a suitable syngeneic recipient strain
for in vivo growth, one potential strategy to overcome
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immunogenicity of the TAg transgene proteins is to
grow MOVCAR cells in tumor-prone C57BL/6 TgMISIIR-TAg-DR6 transgenic mice. We hypothesized that
removal of the ovaries of young TgMISIIR-TAg-DR26
transgenic mice might abrogate tumor development and
render these mice suitable for engraftment of MOVCAR
cells. In addition to TAg expression detected in tumor
cells, TAg staining was also commonly observed in the
uterine and fallopian tube epithelia of 28 day-old mice
(Figure 3 and [28]), although neither uterine nor fallopian tube carcinomas were observed at the time of
euthanasia. However, it is possible that ovarian carcinoma development was sufficiently rapid that it outpaced carcinoma development in the endometrium or
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oviduct. To determine whether removal of the ovaries
from TgMISIIR-TAg-DR26 transgenic mice was sufficient to inhibit tumor formation, a series of oophorectomy experiments were performed (summarized in Table
2). Mice were oophorectomized between four and six
weeks of age, which is prior to the age of onset of
cyclivity at 48 days in C57BL/6 mice [53] and prior to
any obvious enlargement of the ovaries (Figure 3, [28]
and data not shown). Female C57BL/6 TgMISIIR-TAgDR26 transgenic mice were subjected to the following
surgical manipulations: 1) bilateral oophorectomy (n =
9), 2) bilateral oophorectomy and salpingectomy (n = 5)
and 3) bilateral oophorectomy and salpingectomy with
removal of the ovarian bursa (n = 8) and the results are

Figure 3 Early tumor formation in TgMISIIR-TAg-DR26 mice. The presence and extent of tumor formation in a 28-day old female TgMISIIRTAg-DR26 mouse was confirmed by histopathological evaluation. A) Low power magnification (40x) of an H&E stained section of the
reproductive tract showing the ovary and segments of the fallopian tube and uterus reveals an early-stage ovarian tumor indicated by the
arrow. B) Immunostaining of an adjacent section shows TAg positive tumor cells in the ovary (arrowheads). TAg positive staining cells were also
apparent in the epithelium of the fallopian tube and endometrium. The segment contained within the box is shown in (C) at higher
magnification (100X). D) High power magnification (400X) of the boxed area in (C) showing the TAg positive epithelial cells of the endometrial
glands. Calibration bar: A and B, 1 mm; C, 250 μm; D, 125 μm.
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summarized in Table 2. Tumor formation was detected
in most mice and histopathological evaluation revealed
the presence of carcinomas that were similar to those
that occurred spontaneously in TgMISIIR-TAg-DR26
transgenic mice. Tumors arising in the TgMISIIR-TAgDR26 mice in which the ovarian bursa was removed at
the time of bilateral oophorectomy and salpingectomy
were widely disseminated in the peritoneal cavity and
resembled primary peritoneal carcinomatosis. The origin
of the tumors remains uncertain as 28 day-old mice
already exhibited the presence of TAg positive tumor
cells in the ovary and TAg positive cells in the fallopian
tube and uterus (Figure 3 and [28]). Tumors arising in
ovariectomized mice may originate from residual tumor
cells shed from the ovaries prior to the time of surgery,
or alternatively, from TAg positive cells present in the
fallopian tubes or the uterus. Although we cannot definitively distinguish between these possibilities, the histology of tumors arising in oophorectomized mice
resembled the high-grade serous ovarian adenocarcinomas and disseminated peritoneal carcinomatosis that
occurs spontaneously in TgMISIIR-TAg-DR26 mice suggesting that ovarian tumors arise from the ovaries and/
or fallopian tube and that tumor initiation occurs early
in these mice. There was no evidence of endometrial
carcinomas in any of the groups, suggesting that
although the SV40 TAg transgene protein is expressed
in the endometrium, this expression is not sufficient for
full oncogenic transformation of this tissue. Importantly,
as surgical removal of the ovaries and oviduct are not
sufficient to prevent tumor development, these mice are
unsuitable as allograft hosts for implantation of MOVCAR cells.

were female, and as previously reported [27], 18/36
(50%) developed early onset, bilateral, moderately to
poorly differentiated ovarian carcinomas with widespread peritoneal dissemination. Tumors exhibiting differentiated morphology resembled high-grade serous
EOCs. Among the remaining female founders, 3/36 (8%)
developed non-ovarian tumors and 15/36 (42%) lacked
detectable TAg transgene protein expression, failed to
transmit the transgene or failed to breed. Therefore,
TAg positive male founders were bred and offspring
were analyzed to identify stable transgenic lines of mice
that transmitted the TAg transgene. Similar to female
TgMISIIR-TAg founder mice, male founders were frequently infertile, sub-fertile or did not transmit transgene expression. Among the fertile transgenic lines
established from TgMISIIR-TAg male founders, several
exhibited TAg transgene expression in the fallopian
tubes of female offspring without obvious pathology.
Further phenotypic characterization of female offspring
of two of these transgenic lines, TgMISIIR-TAg-DQ62
and TgMISIIR-TAg-EE73, showed that although the
mice expressed the TAg transgene, they exhibited normal fertility and lifespan and failed to develop tumors.
The expression of TAg protein in these mice was
detected in a limited number of epithelial cells lining
the fallopian tube (Figure 4). These transgenic lines are
referred to as “TgMISIIR-TAg-Low” mice due to the
relatively limited expression of TAg protein. Previous
work [54] suggested that because these mice normally
expressed the TAg protein and exhibited little or no
susceptibility tumor formation, they could serve as suitable hosts for implantation of TAg expressing MOVCAR
cells.

Phenotypes of TgMISIIR-TAg transgenic mice

MOVCAR cells grow as i.p. and orthotopic allografts in
C57BL/6 TgMISIIR-TAg-Low recipients

As an alternative means to circumvent the problem of
TAg immunogenicity in recipient mice, we used a strategy previously described by Mintz and Silvers [54] in
which inbred transgenic mice with low expression of the
tumor promoting transgene, and hence little or no susceptibility to tumor formation, were utilized as allograft
recipients. To identify such transgenic lines, we isolated
and phenotypically analyzed a total of 96 TAg positive
TgMISIIR-TAg transgenic founders. Among these, 36
Table 2 Oophorectomized TgMISIIR-TAg transgenic mice
develop epithelial tumors
Surgical procedure

Number of mice with
tumors

1) Remove TgMISIIR-TAg ovaries

9/9

2) Remove TgMISIIR-TAg ovaries and fallopian
tubes

4/5

3) Remove TgMISIIR-TAg ovaries, fallopian
tubes and bursa

6/8

Prior to testing whether the TgMISIIR-TAg-Low transgenic lines, DQ62 and EE73, could serve as recipients
for allografted MOVCAR cells, each was backcrossed to
wild type C57BL/6 mice for a minimum of ten generations to ensure genetic purity. No changes in TAg
expression patterns in the reproductive tracts of female
mice were observed during the backcrossing process. To
test whether MOVCAR cells could be grown as allografts in female C57BL/6 TgMISIIR-TAg-Low transgenic
mice, three TgMISIIR-TAg-DQ62 mice and three TgMISIIR-TAg-EE73 mice were each injected i.p. with 2 × 107
MOVCAR 12 cells. Similar to SCID mice, C57BL/6
TgMISIIR-TAg-DQ62 and TgMISIIR-TAg-EE73 mice
injected i.p. with MOVCAR 12 cells developed tumors
that necessitated euthanasia within three months (Figure
5 and Table 3). At necropsy, disseminated peritoneal
tumors were detected and several mice exhibited
enlarged ovaries. In addition to the presence of
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Figure 4 TgMISIIR-TAg-EE73 and TgMISIIR-TAg-DQ62 mice exhibit restricted TAg expression. Histopathological evaluation of H&E (a-d) and
TAg (e-h) stained sections of female TgMISIIR-TAg-EE73 (a, b, e and f) and TgMISIIR-TAg-DQ62 (c,d, g and h) mice show TAg positive cells present
in the oviduct (e and g), but not in the OSE and bursal epithelium of the same mice (f and h). All micrographs were taken at the same
magnification and the calibration bar shown in panel h corresponds to 100 μm.

disseminated peritoneal adenocarcinoma infiltrating the
pancreas, omentum, mesentery, diaphragm and abdominal wall, histopathological review of H&E and TAg
stained sections revealed the presence of tumor cells
growing within the intrabursal space surrounding the
ovaries and within the ovarian cortex of both the
C57BL/6 TgMISIIR-TAg-DQ62 and TgMISIIR-TAg-EE73
mice (Figure 5 and Table 3). Detection of the TAg positive tumor cells in the ovaries of both SCID (Figure 1)
and syngeneic C57BL/6 TgMISIIR-TAg-Low mice (Figure 5) suggests that MOVCAR cells exhibit a strong
propensity for organotropic homing to ovary. To ensure
that the observed results were not cell line-specific, five
additional MOVCAR cell lines (MOVCAR 5009, 5025,
5183, 5447 and 5612) were tested for tumorigenic
potential following i.p. and i.b. injection. All five cell
lines tested grew as allografts in C57BL/6 TgMISIIRTAg-Low mice (Figure 6, Table 3 and data not shown)
producing disseminated peritoneal adenocarcinoma frequently accompanied by intrabursal and intra-ovarian
tumor growth. Like the allograft experiments performed
in SCID mice, individual cell lines exhibited differences
in tumor latency and dissemination pattern in C57BL/6
TgMISIIR-TAg-Low mice. However, the tumor latency

and dissemination pattern for any individual cell line are
similar in SCID and C57BL/6 TgMISIIR-TAg-Low allograft recipients (compare data summarized in Tables 1
and 3). Taken together, these results show that both
lines of C57BL/6 TgMISIIR-TAg-Low mice can serve as
immunocompetent syngeneic recipients for the growth
of MOVCAR tumor cells isolated from individual tumor
bearing C57BL/6 TgMISIIR-TAg-DR6 mice.
Tumor growth in TgMISIIR-TAg-Low mice can be
monitored in vivo by bioluminescent imaging

Although orthotopic or pseudo-orthotopic implantation
of EOC cells represents a more highly relevant tumor
microenvironment for tumor growth, there are inherent
difficulties in detection and quantitation of tumor
growth and progression in deeply embedded tumors
growing within the intrabursal space or as disseminated
peritoneal disease. To facilitate detection and quantitation of tumor growth in vivo, MOVCAR 5009 and 5447
cells were transduced with a retroviral construct encoding firefly luciferase. Stably transduced cells were
implanted into C57BL/6 TgMISIIR-TAg-Low mice by i.p.
or i.b. injection and tumor growth was then monitored
non-invasively by bioluminescent imaging (BLI).
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TgMISIIR-TAg-Low mice injected i.b. with 8.0 × 10 5
MOVCAR-5009-Luc (mouse numbers EE73 7245 and
EE73 7263) or MOVCAR-5447-Luc (mouse numbers
EE73 7244 and EE73 7261) cells (Figure 7). Tumor
growth was monitored by BLI for up to 11 weeks and
showed that orthotopic implantation of cells resulted in
proscribed luminescent signals that were confined to the
site of intrabursal injection in both SCID and C57BL/6
TgMISIIR-TAg-Low mice (Figure 7 and Table 4).
Although the same numbers of cells were injected in all
mice, signal intensities appear stronger in SCID mice due
to the lack of pigment and therefore, are not directly
comparable to BLI signals in the C57BL/6 TgMISIIRTAg-Low mice. In vitro, MOVCAR-5009-Luc cells grow
much more rapidly than MOVCAR-5447-Luc cells. This
pattern was also observed in vivo, with rapid acceleration
of tumor growth detected three weeks post injection of
MOVCAR-5009-Luc cells, while signal intensities
detected in mice injected with MOVCAR-5447-Luc cells
did not increase significantly until ten weeks post injection (Figure 7). Taken together, these data show that
growth of MOVCAR cells engineered to express firefly
luciferase can be monitored non-invasively by BLI and
that differences in in vivo growth rates of individual
MOVCAR cell lines can be detected using this method.

Figure 5 MOVCAR 12 cells are tumorigenic in TgMISIIR-TAgDQ62 and TgMISIIR-TAg-EE73 mice. Micrographs of tumors arising
in TgMISIIR-TAg-DQ62 (a, c, e and h) and TgMISIIR-TAg-EE7 (b, d, f
and h) mice injected i.p. with 2 × 107 MOVCAR 12 cells. H&E (a, b, e
and f) and TAg (c, d, g and h) stained sections of tumors located
within the ovarian cortex (a-d) and peritoneal tumors invading the
omentum and pancreas (e-h). The tumors were similar to those
described in Figure 1. All micrographs were taken at the same
magnification and the calibration bar shown in panel h corresponds
to 100 μm.

Age matched female C57BL/6 TgMISIIR-TAg-Low
(DQ62) mice injected i.p. with 5.0 × 10 6 MOVCAR5009-Luc cells rapidly developed disseminated peritoneal
carcinomatosis readily detectable by BLI (data not
shown). We predicted that detection of bioluminescent
signal emanating from orthotopically implanted tumors
would be technically more challenging in C57BL/6
TgMISIIR-TAg-Low mice due to the relatively low number of cells that can be implanted by this method (e.g.,
8.0 × 105 cells) and by the presence of black pigment in
the C57BL/6 mice compared to white mice. Therefore,
SCID mice injected i.b. with the same number of either
MOVCAR-5009-Luc or MOVCAR-5447-Luc cells were
used as positive controls for BLI of orthotopically
implanted tumor cells in age-matched female C57BL/6

Discussion
Utilization of animal models with an intact immune system is critical for the evaluation of immune-based therapeutic strategies and vaccine development. An SV40 TAg
transgenic model of prostate cancer [55] has been used to
study the effects of combining blockade of cytotoxic T
lymphocyte antigen 4 (CTLA-4) and vaccination with
granulocyte macrophage colony stimulating factor (GMCSF;Gvax) and subsequent derivatives of this vaccine
strategy [56-60]. The C57BL/6 syngeneic mouse ovarian
cancer model developed by Roby et al, [10] has been used
for studies of the contribution of cells in the tumor microenvironment, including epithelial-stromal cell interactions,
VEGF induced-effects on tumor vasculature and tumor
cell-secreted factors that stimulate cytokine production,
macrophage infiltration and vascularization that favor
tumor growth and progression [14,15,18]. Similar studies
would be difficult to impossible to conduct in immunodeficient mice. The availability of an additional syngeneic
mouse model of EOC will allow cross-comparison of
mouse models and validation of key findings.
The functional utility of animal models of human cancer depends largely on the extent to which the animal
model recapitulates the histology and biological behavior
of the disease in humans. Many transgenic tumor models have been developed using the immediate early
region of the SV40 virus containing the potently oncogenic large and small T antigen (TAg and tag) genes
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Table 3 Growth of MOVCAR cells in TgMISIIR-TAg-Low mice
Host

MOVCAR cell line

# cells injected i.p.

Survival
(days post tumor cell injection)

Tumor location

Ascites
(>1.0 mL)

DQ62

12

2 × 107

96

Peritoneal cavity, invasion of ovarian cortex

+

DQ62
DQ62

12
12

2 × 107
2 × 107

90
96

Peritoneal cavity, invasion of ovarian cortex
Peritoneal cavity, invasion of ovarian cortex

+
+

EE73

12

2 × 107

90

Peritoneal cavity, invasion of ovarian cortex

EE73

12

2 × 107

96

Peritoneal cavity, invasion of ovarian cortex

EE73

12

2 × 107

90

Peritoneal cavity, invasion of ovarian cortex

DQ62

5009

5 × 106

28

Peritoneal cavity

+

DQ62

5009

5 × 106

28

Peritoneal cavity

+

DQ62

5009

5 × 106

28

Peritoneal cavity

+

DQ62
DQ62

5009
5025

5 × 106
5 × 106

28
30

Peritoneal cavity
Peritoneal cavity, invasion of ovarian cortex

+
+

DQ62

5025

1 × 107

30

Peritoneal cavity, invasion of ovarian cortex

+

DQ62

5025

1 × 107

37

Peritoneal cavity, invasion of ovarian cortex

+

DQ62

5025

1 × 107

37

Peritoneal cavity, invasion of ovarian cortex

+

DQ62

5183

2 × 107

108

Peritoneal cavity

DQ62

5183

2 × 107

49

Peritoneal cavity

+

DQ62

5612

1.5 × 107

71

Peritoneal cavity

+

DQ62

5612

1.5 × 107

71

Peritoneal cavity

+

[55,61-66]. The continued utility of SV40 TAg models in
studying cancer is underscored by seminal contributions
to our understanding of the “angiogenic switch” [67-71]
and tumor progression and invasion [72]. Importantly, a
recent study [73] identified an integrated gene expression signature from three distinct TAg mouse models (i.
e., mammary, prostate and lung cancer models) that is
comparable to a signature associated with the aggressive
biological behavior and prognosis for several human
epithelial tumors, including breast cancers. Results from
this study showed that tumors arising in TAg-based
mouse models share common features of gene expression with human cancer and are relevant preclinical
models [73].
Female transgenic C57BL/6 TgMISIIR-TAg-DR26 mice
develop spontaneous bilateral ovarian carcinoma with
100% penetrance [28]. Tumor progression in these mice
is characterized by widespread peritoneal dissemination
and the development of malignant ascites and tumor
morphology and histology of the tumors closely resembles high-grade serous adenocarcinomas, the most common histologic subtype of EOC detected in women.
Tumors and cell lines derived from primary tumors and
ascites of tumor bearing mice exhibit several characteristics in common with human EOC cell lines and
tumors including AKT/mTOR activation, COX1 overexpression and VEGF overexpression and secretion
([28,44-47] and the present study). In addition, a verapimil-sensitive Hoescht dye-excluding ovarian carcinoma
side population (SP), a potential population of ovarian
cancer initiating cells, was identified in MOVCAR cell

lines [48]. Ovarian tumors arising in C57BL/6 TgMISIIR-TAg-DR26 mice are sensitive to standard combination platinum and taxane chemotherapy and to mTOR
inhibition with Everolimus (RAD001) [28,45]. These
observations underscore the potential utility of these
transgenic mice for preclinical evaluation of therapeutic
agents. However, reflecting its relation to the biology of
human EOC, tumor formation in this transgenic model
is also stochastic, resulting in variation in the latency of
tumor formation and time to metastasis. This necessitates relatively large cohorts of mice and non-invasive
longitudinal in vivo imaging such as MRI to optimize
results of therapeutics studies.
To overcome the limitations encountered with spontaneous tumor development, we isolated individual transgenic lines of non-tumor prone C57BL/6 TgMISIIR-TAg
transgenic mice that can serve as syngeneic immunocompetent hosts for allografted TAg expressing MOVCAR cells isolated from tumor bearing C57BL/6
TgMISIIR-TAg-DR26 mice. Syngeneic mouse models of
EOC in which spontaneously transformed ID-8 MOSEC
grown as allografts in C57BL/6 recipients [10] or HM-1
tumor cells grown as allografts in B6C3F1 recipients
[74] have been previously described. These syngeneic
models have been used successfully for preclinical evaluation of therapeutic agents and studies of the role of
the tumor microenvironment on ovarian tumor growth
and progression [11-18,75]; however, these models each
rely on single mouse ovarian carcinoma cell lines in
which the underlying molecular mechanisms of malignant transformation remain undefined.
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Figure 6 Pseudo-orthotopic and orthotopic implantation of MOVCAR cell in TgMISIIR-TAg-Low mice. H&E (a, c, e, g, I, k, m and o) and
TAg (b, d, f, h, j, l, n and p) stained sections of tumors arising in TgMISIIR-TAg-Low mice injected i.p (a-h) or i.b. (i-p) with MOVCAR 5009 (a, b, e,
f, i, j, m and n) and 5447 (c, d, g, h, k, l, o and p) cells. The tumors are similar to those shown in the previous figures, i.e., poorly differentiated
carcinomas with few areas of tubular differentiation and occasional papillary structures, e.g., panels c and g. All micrographs were taken at the
same magnification and the calibration bar shown in panel p corresponds to 100 μm.

The ease of establishment of TAg-transformed
MOVCAR cell lines in culture has enabled the isolation of a large number of distinct cell lines, several of
which are described in the present study. Although
derived from an inbred strain of mice, the stochastic
manner in which tumors arise in C57BL/6 TgMISIIRTAg-DR26 mice results in intrinsic differences in
MOVCAR cell lines derived from individual tumorbearing mice. MOVCAR cell lines grown in culture
exhibit different growth rates and expression of proteins associated with EOC, such as levels of secreted
VEGF. These cell lines also exhibit differences when
grown in vivo. For example, some cells lead to very
rapid growth and production of voluminous malignant
ascites, whereas other cells are slower growing and
produce less ascites. Interestingly, the cell lines that
result in the highest levels of ascites production in vivo
are the cell lines that exhibit the highest levels of

VEGF secretion in vitro. These observations suggest
that although the primary oncogenic stimulus driving
tumorigenesis in C57BL/6 TgMISIIR-TAg-DR26 transgenic mice is the same in all animals, there are likely
additional genetic, epigenetic and/or gene expression
alterations that contribute to ovarian tumor progression, and identification of these alterations may contribute to our understanding of human EOC. Moreover,
once identified, the role of specific alterations in gene
function in ovarian tumorigenesis can be studied in
these cell lines as they are readily amenable to direct
manipulation using established strategies for ectopic
gene expression or RNA interference.
With regard to preclinical evaluation of novel therapeutic
agents, our syngeneic mouse model of EOC provides several advantages. First, tumors are grown in fully immunocompetent mice enabling the evaluation of vaccine and
immune-based therapeutic strategies. Second, TgMISIIR-
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Figure 7 Orthotopic tumor growth in TgMISIIR-TAg-Low mice monitored and quantified in vivo by BLI. SCID and TgMISIIR-TAg-EE7 mice
were given unilateral or bilateral intrabursal injections with 2 × 105 MOVCAR 5009 or 5447 cells and subjected to weekly bioluminescent
imaging to monitor tumor growth. A) Quantitative analysis of total photon counts from dorsal images of TgMISIIR-TAg-EE7 mice injected i.b. with
MOVCAR 5009 cells (mice 7245 and 7263) and MOVCAR 5447 cells (mice 7244 and 7261). B) Dorsal images of control SCID and TgMISIIR-TAg-EE7
mice injected i.b. with MOVCAR 5009 cells (mice 7245 and 7263) and MOVCAR 5447 cells (mice 7244 and 7261) showing proscribed luminescent
signals at the site of unilateral (mice 7245 and 7244) or bilateral (mice 7263 and 7261) i.b. injection.

TAg-Low transgenic mice have been fully backcrossed to a
pure C57BL/6 genetic background, exhibit normal fertility
and lifespan and do not develop tumors. Thus, large
cohorts of mice can be established for synchronous allograft initiation without interference of tumor growth
initiated from the host. Third, the availability of multiple

distinct MOVCAR cells lines for evaluation avoids issues of
cell line-specific effects, and because MOVCAR cells are
easily manipulated in culture, on-target effects of therapeutics can be confirmed in parallel using RNAi based strategies for direct target knockdown. Finally, the ability to
easily express reporter genes in MOVCAR cells facilitates
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Table 4 Intrabursal growth of MOVCAR-Luciferase cells in TgMISIIR-TAg-Low mice
Host

MOVCAR cell
line

# cells injected
i.b.

site of
injection

Survival
(days post tumor cell
injection)

EE73

5009

8 × 105

left

50

n/a

167

+

EE73

5009

8 × 105

bilateral

50

151

176

+

EE73
EE73

5447
5447

8 × 105
8 × 105

left
bilateral

81
81

n/a
32

57
76

Right ovary tumor
volume
(mm3)

Left ovary tumor
volume
(mm3)

Ascites
(>1.0
mL)

n/a: not applicable

strategies for non-invasive in vivo optical imaging such as
bioluminescent, fluorescent and near infrared fluorescent
imaging.

Conclusions
In conclusion, we have developed an immunocompetent
syngeneic mouse model of EOC consisting of C57BL/6
TgMISIIR-TAg-Low transgenic mice that can serve as
immunocompetent syngeneic allograft recipients for
MOVCAR cell lines. Based on distinct characteristics of
these cell lines and their amenability to in vitro manipulation of gene expression, this model represents a flexible system to study ovarian tumor biology and to
evaluate the efficacy of novel therapeutic strategies.
Additional material
Additional file 1: Levels of secreted VEGF protein in MOVCAR cells.
The amount of secreted VEGF protein present in conditioned medium of
seven independent MOVCAR cell lines was determined by ELISA assay.
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